This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Immune Design Poised on Progress of Pipeline Candidates
by Zacks Equity Research
Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.
Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agenus (AGEN) posts wider-than-expected loss and misses on revenue estimate in the fourth quarter of 2017.
Should Value Investors Pick Merck & Co. (MRK) Stock Now?
by Zacks Equity Research
Let's see if Merck & Co., Inc. (MRK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Dow 30 Stock Roundup: Boeing JV Wins $354M Satellite Contract, Merck's Keytruda Gets Priority Review
by Swarup Gupta
The Dow traversed a difficult week, declining over three consecutive trading sessions.
Merck's Keytruda Gets Priority Review for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.
AstraZeneca's Final Data From Key Lung Cancer Study Delayed
by Zacks Equity Research
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
The Zacks Analyst Blog Highlights: Merck, McDonald's, Broadcom, Activision and Marvell
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, McDonald's, Broadcom, Activision and Marvell
Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug
by Zacks Equity Research
Merck (MRK) is going to pay $300 million upfront to Japan's Eisai to jointly develop and commercialize the latter's pipeline candidate Lenvima.
Top Research Reports for Merck, McDonald's & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), McDonald's (MCD) and Broadcom (AVGO).
AstraZeneca's Forxiga Label Expansion Filing Accepted in EU
by Zacks Equity Research
AstraZeneca's (AZN) submission for label expansion of diabetes drug Forxiga accepted by the European Medicines Agency.
Are Alzheimer's-Focused Stocks Set for a Financial Windfall?
by Zacks Equity Research
Launch of the blood tests will help companies focused on developing preventive treatments make billions.
Merck (MRK) Down 9.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Q4 Loss Narrower Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.
Horizon Pharma (HZNP) Tops Q4 Earnings, Provides 2018 View
by Zacks Equity Research
Horizon Pharma (HZNP) Q4 results are driven by growth from the orphan unit and the rheumatology business.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Down Y/Y
by Zacks Equity Research
Bayer AG's (BAYRY) fourth-quarter 2017 core earnings per share from continuing operations beat estimates.
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
The Zacks Analyst Blog Highlights: Walmart, Chevron, ExxonMobil, Travelers and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Chevron, ExxonMobil, Travelers and Merck
The Zacks Analyst Blog Highlights: Walmart, Chevron, ExxonMobil, Travelers and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Chevron, ExxonMobil, Travelers and Merck
Dow 30 Stock Roundup: Walmart Disappoints, Coca-Cola Impresses
by Swarup Gupta
The Dow experienced a volatile holiday shortened week, suffering losses during two trading sessions.
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
by Zacks Equity Research
Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.
What's in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, in combination with the other party's Opdivo and Opdivo plus Yervoy.